Categories
Latest Industry Intelligence
Discover the groundbreaking findings from a study on bispecific T cell engagers conducted by The [...]
A new Guide is now available for download from NanoTemper. The development of a successful [...]
The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the Phase III KEYNOTE-966 clinical trial. The results were presented at the AACR Annual Meeting 2023, held April 14-19 and published in The Lancet. Biliary tract cancers are rare […]
Patients with treatment-naïve resectable non-small cell lung cancer (NSCLC) who received neoadjuvant durvalumab (Imfinzi) plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival (EFS) and pathological complete response (pCR) compared with those who received neoadjuvant chemotherapy alone. The results from the Phase III placebo-controlled AEGEAN clinical trial were presented at the AACR Annual Meeting […]
Adjuvant therapy with atezolizumab (Tecentriq) and bevacizumab (Avastin) increased recurrence-free survival of patients with hepatocellular carcinoma (HCC) following surgical resection or ablation, according to the results from a Phase III trial. The results of the IMbrave050 clinical trial were presented at the AACR Annual Meeting 2023, held April 14-19. The mainstays of curative therapies for […]
A new, oral, first-in-class experimental cancer drug has shown potent activity against cancer cells and caused shrinkage of hard-to-treat human ovarian tumours grown in mice, a new study shows. The drug, which is now called NXP800 and has already entered a Phase I clinical trial, was discovered by scientists at The Institute of Cancer Research, […]
This latest ebook sponsored by Sino Biological features insight on how the global drug discovery and development sector is making breakthroughs in cancer research. Download this exclusive eBook to learn more about: The global developments tackling the burden of cancer Advances and challenges in cancer drug discovery The ‘dark matter’ behind cancer The drug that may […]
Researchers at the University of East Anglia have developed a new drug that works against all of the main types of primary bone cancer. The study shows how a breakthrough drug called CADD522 blocks a gene associated with driving the cancer’s spread in mice implanted with human bone cancer. The drug increases survival rates by […]
China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for enfortumab vedotin for urothelial cancer. The approval is in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy. “In China, there were nearly 86,000 new cases of bladder cancer […]
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As well as providing extensive coverage of the SLAS2023 meeting in San Diego and Rare Disease Day, DDW has also reported on a number of developments […]
News round-up for 27 February – 3 March by DDW Digital Content Editor Diana Spencer. As well as providing extensive coverage of the SLAS2023 meeting in San Diego and Rare Disease Day, DDW has also reported on a number of developments in cancer drug discovery this week. Most notably, a 20-year mystery regarding the ‘dark matter’ of the […]
Menu ≡ ╳ 
